Serina Therapeutics Inc Reports Cohort 1 Observations From Ser-252 Registrational Study In Advanced Parkinson’s Disease And Advances To Cohort 2 S SERA • 2026-09-09 Cohort 1 observations and move to Cohort 2
Sept. 9 (Reuters) - Serina Therapeutics, Inc. SERA:
Serina Therapeutics Inc reports cohort 1 observations from Ser-252 registrational study in advanced Parkinson’s disease and advances to cohort 2
Serina Therapeutics expects to report topline data from the single-ascending-dose portion of the study in first half of 2027
Blinded cohort 1 observations showed pharmacokinetic profile consistent with sustained apomorphine exposure Ser-252
Serina Therapeutics Inc Reports Cohort 1 Observations From Ser-252 Registrational Study In Advanced Parkinson’s Disease And Advances To Cohort 2 - SERA News | Rallies
SERA•
